PharmaMar’s 30% plunge triggers valuation cuts and new short sellersExecutive summary: PharmaMar's shares fell roughly 30% after a failed Zepzelca trial, prompting valuation cuts. The decline signals market skepticism about the company's pipeline and could limit its ability to raise capital. PharmaMar, biotech analysts, short sellers, and Spanish regulators. The company may seek a capital increase or partnership, while investors monitor further trial updates.PharmaMar's share price dropped about 30% after disappointing Zepzelca trial results, prompting valuation downgrades and attracting new bearish analysts. The company attempted to stabilize the price but faces sustained downward pressure. The episode reflects heightened scrutiny of biotech pipelines and increasing short‑selling activity in the sector.Connected developmentsEuropean and US stocks seen as portfolio balancersOpen the full case file on Beyond →
Social Pulse
AI estimate · not scraped